Literature DB >> 28570793

Anticonvulsant Medication Use in Veterans With Posttraumatic Stress Disorder.

Brian Shiner1,2,3, Christine Leonard Westgate2, Nancy C Bernardy3,4, Paula P Schnurr3,4, Bradley V Watts3,5.   

Abstract

OBJECTIVE: Anticonvulsants have been studied for many indications, including posttraumatic stress disorder (PTSD). The limited efficacy research on anticonvulsants for PTSD is mixed. However, anticonvulsants are prescribed widely to veterans with PTSD. Our objective was to measure trends and factors associated with anticonvulsant prescriptions among veterans with PTSD.
METHODS: We obtained administrative and pharmacy data for veterans who initiated PTSD treatment in the US Department of Veterans Affairs (VA) between 2004 and 2013 (N = 731,520). We identified those who received anticonvulsants during the year following their initial clinical PTSD diagnosis and examined common indications for anticonvulsant use, patient characteristics, and service use characteristics. Using logistic regression, we determined the predictors of anticonvulsant initiation among those without an indication.
RESULTS: Although 24.9% of patients in the cohort received an anticonvulsant during their initial year of PTSD treatment, 94.6% had an indication unrelated to PTSD and 51.2% initiated anticonvulsant use before their PTSD diagnosis. While there was growth in anticonvulsant initiation over the 10-year period, this was explained both by growth in indications unrelated to PTSD and by increased use of anticonvulsants for these indications. The rate of anticonvulsant initiation without an indication was stable at approximately 5% throughout the period, with patient and service use characteristics driving the selection of individual agents.
CONCLUSIONS: A large and increasing proportion of veterans with PTSD receives anticonvulsant prescriptions. However, this may be appropriate use driven by increased prevalence of comorbid conditions that may be an indication for anticonvulsant use, including pain and headache disorders. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570793      PMCID: PMC6151858          DOI: 10.4088/JCP.16m11031

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   5.906


  29 in total

1.  Concordance between psychotropic prescribing for veterans with PTSD and clinical practice guidelines.

Authors:  Shaili Jain; Mark A Greenbaum; Craig Rosen
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

2.  The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder.

Authors:  Jonathan R T Davidson; Kathleen Brady; Thomas A Mellman; Murray B Stein; Mark H Pollack
Journal:  J Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.153

3.  Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study.

Authors:  K M Connor; S M Sutherland; L A Tupler; M L Malik; J R Davidson
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

Review 4.  Neurobiological sensitization models of post-traumatic stress disorder: their possible relevance to multiple chemical sensitivity syndrome.

Authors:  M J Friedman
Journal:  Toxicol Ind Health       Date:  1994 Jul-Oct       Impact factor: 2.273

5.  Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy.

Authors:  M B Hamner; P S Brodrick; L A Labbate
Journal:  Ann Clin Psychiatry       Date:  2001-09       Impact factor: 1.567

6.  A meta-analysis of topiramate's effects for individuals with alcohol use disorders.

Authors:  Janet C Blodgett; A C Del Re; Natalya C Maisel; John W Finney
Journal:  Alcohol Clin Exp Res       Date:  2014-05-05       Impact factor: 3.455

Review 7.  Anticonvulsants to treat post-traumatic stress disorder.

Authors:  Hee Ryung Wang; Young Sup Woo; Won-Myong Bahk
Journal:  Hum Psychopharmacol       Date:  2014-09       Impact factor: 1.672

8.  Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial.

Authors:  Steven L Batki; David L Pennington; Brooke Lasher; Thomas C Neylan; Thomas Metzler; Angela Waldrop; Kevin Delucchi; Ellen Herbst
Journal:  Alcohol Clin Exp Res       Date:  2014-08-04       Impact factor: 3.455

Review 9.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

Authors:  Michael A Rogawski; Wolfgang Löscher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

10.  A preliminary controlled trial of divalproex in posttraumatic stress disorder.

Authors:  Mark B Hamner; Richard A Faldowski; Sophie Robert; Helen G Ulmer; Michael David Horner; Jeffrey P Lorberbaum
Journal:  Ann Clin Psychiatry       Date:  2009 Apr-Jun       Impact factor: 1.567

View more
  7 in total

1.  Using patient-reported outcomes to understand the effectiveness of guideline-concordant care for post-traumatic stress disorder in clinical practice.

Authors:  Brian Shiner; Jiang Gui; Christine Leonard Westgate; Paula P Schnurr; Bradley V Watts; Sarah L Cornelius; Shira Maguen
Journal:  J Eval Clin Pract       Date:  2019-05-21       Impact factor: 2.431

2.  Measuring Use of Evidence-Based Psychotherapy for PTSD in VA Residential Treatment Settings with Clinician Survey and Electronic Medical Record Templates.

Authors:  Brian Shiner; Christine Leonard Westgate; Vanessa Simiola; Richard Thompson; Paula P Schnurr; Joan M Cook
Journal:  Mil Med       Date:  2018-09-01       Impact factor: 1.437

3.  Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.

Authors:  Patricia T Spangler; James C West; Catherine L Dempsey; Kyle Possemato; Danielle Bartolanzo; Pablo Aliaga; Carlos Zarate; Meena Vythilingam; David M Benedek
Journal:  J Clin Psychiatry       Date:  2020-10-27       Impact factor: 4.384

4.  Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications.

Authors:  Brian Shiner; Jenna A Forehand; Luke Rozema; Martin Kulldorff; Bradley V Watts; Marina Trefethen; Tammy Jiang; Krista F Huybrechts; Paula P Schnurr; Matthew Vincenti; Jiang Gui; Jaimie L Gradus
Journal:  Biol Psychiatry       Date:  2021-10-20       Impact factor: 13.382

5.  Causes of Excess Mortality in Veterans Treated for Posttraumatic Stress Disorder.

Authors:  Jenna A Forehand; Talya Peltzman; Christine Leonard Westgate; Natalie B Riblet; Bradley V Watts; Brian Shiner
Journal:  Am J Prev Med       Date:  2019-06-24       Impact factor: 6.604

6.  A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice.

Authors:  Brian Shiner; Christine Leonard Westgate; Jiang Gui; Shira Maguen; Yinong Young-Xu; Paula P Schnurr; Bradley V Watts
Journal:  J Clin Psychiatry       Date:  2018-09-18       Impact factor: 5.906

7.  Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.

Authors:  Matthias A Reinhard; Johanna Seifert; Timo Greiner; Sermin Toto; Stefan Bleich; Renate Grohmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-12-28       Impact factor: 5.270

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.